Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Long-Term Debt Repayments (2021 - 2022)

Treace Medical Concepts (TMCI) has disclosed Long-Term Debt Repayments for 2 consecutive years, with -$33.9 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Long-Term Debt Repayments changed N/A year-over-year to -$33.9 million, compared with a TTM value of -$33.9 million through Dec 2023, changed N/A, and an annual FY2021 reading of $1.8 million, changed N/A over the prior year.
  • Long-Term Debt Repayments was -$33.9 million for Q4 2022 at Treace Medical Concepts, down from $33.9 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $33.9 million in Q2 2022 and bottomed at -$33.9 million in Q4 2022.